Gilead exec suggests lower cost for ledipasvir than Sovaldi

Comments by a Gilead Sciences Inc. (NASDAQ:GILD) executive during the company's 2Q14 earnings call suggest the company may not price HCV therapeutic ledipasvir ( GS-5885) as high as Sovaldi sofosbuvir. EVP of Commercial Operations Paul Carter said Gilead hasn't finalized pricing for its fixed-dose combination of Sovaldi and ledipasvir, but that the company feels the "majority of the value" of the combination is in Sovaldi. The combination is under Priority Review at FDA with an Oct. 10 PDUFA date and is also under accelerated assessment in the EU.

Gilead, which released its earnings after market close on Wednesday, reported 2Q14 financial results that beat the Street, including $3.5 billion in Sovaldi sales (see BioCentury Extra, July 23). ...